Co-Authors
This is a "connection" page, showing publications co-authored by SHARON HERMES GIORDANO and JENNIFER LITTON.
Connection Strength
0.430
-
Erratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2016 08; 159(1):201.
Score: 0.141
-
Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2016 Jan; 155(1):165-73.
Score: 0.135
-
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
Score: 0.040
-
BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist. 2015 Jun; 20(6):593-7.
Score: 0.032
-
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
Score: 0.030
-
Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. J Cancer. 2013; 4(7):549-56.
Score: 0.029
-
Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer. 2010 Sep 01; 116(17):4168-77.
Score: 0.023